We provide answers, so you can focus on care
We’re moving exome and genome from specialized tests to standard of care, improving patients’ lives by building towards a future where we can sequence DNA once and analyze the results for a lifetime.
We’re a leader in genomics, with over 400,000 clinical exome and genome tests interpreted and delivered. We offer premier expertise in exome sequencing for pediatric conditions and rare and ultra-rare genetic diseases.
Centrellis®, our proprietary health intelligence platform, integrates digital tools with artificial intelligence, allowing us to ingest and synthesize clinical and genomic data to deliver better health insights.
With one of the world’s largest rare disease data sets, we’re poised to accelerate the use of genomics and leverage large-scale clinical data to enable precision medicine as the standard of care.
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
Jan 9, 2023
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms
Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
Oct. 5, 2022
The largest study of its kind in North America, GUARDIAN is expected to improve population health by identifying more than 250 preventable and treatable conditions